Related Experiment Videos
Problems associated with switch to modafinil - a novel alerting agent in narcolepsy
C Guilleminault1, F A Aftab, D Karadeniz
1Stanford Sleep Disorders Clinic and Research Center, CA 94605, USA. c.guil@leland.stanford.edu
European Journal of Neurology
|September 6, 2000
Summary
Switching patients to modafinil for narcolepsy or idiopathic hypersomnia presents challenges, particularly for those previously on amphetamines. A gradual withdrawal protocol may improve the transition to this new medication.
Area of Science:
- Neurology
- Pharmacology
Background:
- Modafinil is a new treatment for narcolepsy and idiopathic hypersomnia.
- Patients often have prior medication history for their sleep disorders.
Purpose of the Study:
- To outline clinical challenges when switching patients to modafinil.
- To identify patient groups that experience difficulties during this transition.
Main Methods:
- Clinical observation of patients switching to modafinil.
- Comparison of outcomes in medication-naïve patients versus those withdrawn from other medications, specifically amphetamines.
- Assessment of adjunctive therapies like venlafaxine hydrochloride.
Main Results:
- Medication-naïve patients tolerated modafinil best.
- Patients previously treated with amphetamines encountered significant difficulties and withdrawal failures.
- Combining modafinil with venlafaxine hydrochloride effectively managed cataplexy.
Conclusions:
- Switching to modafinil can be challenging, especially for patients with prior stimulant use.
- A progressive withdrawal strategy is recommended to mitigate difficulties during the transition.
- Venlafaxine hydrochloride may be a useful adjunct for managing cataplexy in patients on modafinil.